It's all in a cup of "tea"
MetadataShow full item record
Background Albuminuria as determined from easily collected spot urine or 24 hour urine samples reflects general vascular damage, associates with left ventricular hypertrophy, and predicts adverse cardiovascular and renal outcomes. However, this easily measurable and low cost marker of cardiovascular risk is not yet included in the European, American and South African hypertension guidelines and evidence in Africans is limited. Methods We provide evidence of the usability of this marker in four papers from three different studies, i.e., the Sympathetic and Ambulatory and Ambulatory Blood Pressure in Africans (SABPA), the Prospective Urban Rural Epidemiological (PURE) study and the combination of the prospective ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and The Telmisartan Randomised AssessmeNt Study in ACE iNtoleranT subjects with cardiovascular Disease (TRANSCEND) trials.